← All trials
NCT05652894
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2022
- Primary completion
- Jan 19, 2026
- Completion date
- Oct 20, 2028
- First posted
- Dec 15, 2022
- Last posted
- Dec 15, 2022
- Enrollment
- 190
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Taizhou Hanzhong biomedical co. LTDLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.